Evidence map›Paper›PMID 33552387›Full record

ReviewOxidative medicine and cellular longevity2021

Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives.

Evgeny A Ermakov, Elena M Dmitrieva, Daria A Parshukova, Daria V Kazantseva, Alisa R Vasilieva, Liudmila P Smirnova

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07759895 (Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia), which is not on this map. Cited by 113 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 9 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07759895 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia

TypeinterventionalSponsorAmit LotanRan2026 to 2029Enrolled80ConditionsSchizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder, Schizophrenia and Predominant Negative SymptomsArmsDeferiprone (DFP), N-Acetyl Cysteine (NAC)
3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 9 syntheses or guidelines pooled it, 210 citations in OpenAlex.

  1. Efficacy and safety of Nrf2 activators for schizophrenia: a systematic review and meta-analysis.European archives of psychiatry and clinical neuroscience · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Evgeny A ErmakovLaboratory of Repair Enzymes, Institute of Chemical Biology and Fundamental Medicine, Siberian Division of Russian Academy of Sciences, Novosibirsk 630090, Russia.ORCID https://orcid.org/0000-0002-1084-6419
Elena M DmitrievaLaboratory of Molecular Genetics and Biochemistry, Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk 634014, Russia.ORCID https://orcid.org/0000-0003-0914-5727
Daria A ParshukovaLaboratory of Molecular Genetics and Biochemistry, Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk 634014, Russia.ORCID https://orcid.org/0000-0003-2760-0252
Daria V KazantsevaSiberian State Medical University, Tomsk 634055, Russia.ORCID https://orcid.org/0000-0001-8050-269X
Alisa R VasilievaSiberian State Medical University, Tomsk 634055, Russia.ORCID https://orcid.org/0000-0002-1636-3899
Liudmila P SmirnovaLaboratory of Molecular Genetics and Biochemistry, Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk 634014, Russia.ORCID https://orcid.org/0000-0003-0083-9124
Russian Academy of Sciences · RUSiberian State Medical University · RUInstitute of Chemical Biology and Fundamental Medicine · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia is recognized to be a highly heterogeneous disease at various levels, from genetics to clinical manifestations and treatment sensitivity. This heterogeneity is also reflected in the variety of oxidative stress-related mechanisms contributing to the phenotypic realization and manifestation of schizophrenia. At the molecular level, these mechanisms are supposed to include genetic causes that increase the susceptibility of individuals to oxidative stress and lead to gene expression dysregulation caused by abnormal regulation of redox-sensitive transcriptional factors, noncoding RNAs, and epigenetic mechanisms favored by environmental insults. These changes form the basis of the prooxidant state and lead to altered redox signaling related to glutathione deficiency and impaired expression and function of redox-sensitive transcriptional factors (Nrf2, NF-

Indexed as

Oxidative StressAnimalsAntipsychotic AgentsGenetic Predisposition to DiseaseHumansOxidation-ReductionSchizophreniaSynaptic TransmissionAntipsychotic Agents

Identifiers

PMID33552387
PMCPMC7847339
OpenAlexW3122208075

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.